Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells.
Azab B, Dash R, Das SK, Bhutia SK, Shen XN, Quinn BA, Sarkar S, Wang XY, Hedvat M, Dmitriev IP, Curiel DT, Grant S, Dent P, Reed JC, Pellecchia M, Sarkar D, Fisher PB. Azab B, et al. Among authors: hedvat m. J Cell Physiol. 2012 May;227(5):2145-53. doi: 10.1002/jcp.22947. J Cell Physiol. 2012. PMID: 21780116 Free PMC article.
Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity.
Dash R, Azab B, Quinn BA, Shen X, Wang XY, Das SK, Rahmani M, Wei J, Hedvat M, Dent P, Dmitriev IP, Curiel DT, Grant S, Wu B, Stebbins JL, Pellecchia M, Reed JC, Sarkar D, Fisher PB. Dash R, et al. Among authors: hedvat m. Proc Natl Acad Sci U S A. 2011 May 24;108(21):8785-90. doi: 10.1073/pnas.1100769108. Epub 2011 May 9. Proc Natl Acad Sci U S A. 2011. PMID: 21555592 Free PMC article.
Targeting Mcl-1 for the therapy of cancer.
Quinn BA, Dash R, Azab B, Sarkar S, Das SK, Kumar S, Oyesanya RA, Dasgupta S, Dent P, Grant S, Rahmani M, Curiel DT, Dmitriev I, Hedvat M, Wei J, Wu B, Stebbins JL, Reed JC, Pellecchia M, Sarkar D, Fisher PB. Quinn BA, et al. Among authors: hedvat m. Expert Opin Investig Drugs. 2011 Oct;20(10):1397-411. doi: 10.1517/13543784.2011.609167. Epub 2011 Aug 19. Expert Opin Investig Drugs. 2011. PMID: 21851287 Free PMC article. Review.
Selected approaches for rational drug design and high throughput screening to identify anti-cancer molecules.
Hedvat M, Emdad L, Das SK, Kim K, Dasgupta S, Thomas S, Hu B, Zhu S, Dash R, Quinn BA, Oyesanya RA, Kegelman TP, Sokhi UK, Sarkar S, Erdogan E, Menezes ME, Bhoopathi P, Wang XY, Pomper MG, Wei J, Wu B, Stebbins JL, Diaz PW, Reed JC, Pellecchia M, Sarkar D, Fisher PB. Hedvat M, et al. Anticancer Agents Med Chem. 2012 Nov;12(9):1143-55. doi: 10.2174/187152012803529709. Anticancer Agents Med Chem. 2012. PMID: 22931411 Free PMC article. Review.
Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480.
Xin H, Herrmann A, Reckamp K, Zhang W, Pal S, Hedvat M, Zhang C, Liang W, Scuto A, Weng S, Morosini D, Cao ZA, Zinda M, Figlin R, Huszar D, Jove R, Yu H. Xin H, et al. Among authors: hedvat m. Cancer Res. 2011 Nov 1;71(21):6601-10. doi: 10.1158/0008-5472.CAN-11-1217. Epub 2011 Sep 15. Cancer Res. 2011. PMID: 21920898 Free PMC article.
The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.
Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, Buettner R, Proia D, Kowolik CM, Xin H, Armstrong B, Bebernitz G, Weng S, Wang L, Ye M, McEachern K, Chen H, Morosini D, Bell K, Alimzhanov M, Ioannidis S, McCoon P, Cao ZA, Yu H, Jove R, Zinda M. Hedvat M, et al. Cancer Cell. 2009 Dec 8;16(6):487-97. doi: 10.1016/j.ccr.2009.10.015. Cancer Cell. 2009. PMID: 19962667 Free PMC article.
15 results